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Background: Asymmetric dimethylarginine (ADMA), the main endogenous inhibitor of nitric oxide synthase, is
considered to be associated with endothelial dysfunction. High ADMA levels have been shown to be related with
disorders causing vascular inflammation such as hypertension, hypercholesterolemia, atherosclerosis, chronic heart
failure, stroke and sepsis. Cutaneous anthrax (CA) is a serious infectious disease which may cause vasculitis. The aim
of the study was to investigate the serum ADMA levels in patients with CA.
Methods: A total of 35 serum samples of the patients with CA and 18 control sera were tested for ADMA levels
using ADMA ELISA kit (Immunodiagnostik AG, Bensheim, Germany).
Results: ADMA levels were found to be significantly higher in the patients group than the controls (p < 0.001). In
addition, ADMA levels were found to be positively associated with sedimentation rates (R = 0.413; p = 0.026), and
inversely associated with international normalized ratio (INR) levels (R = −0.46; p = 0.011). A cut-off value of 0.475 of
ADMA had a sensitivity of 74.3%, specificity of 77.8%, and accuracy of 75.5% in the diagnosis of CA.
Conclusion: Although the exact mechanism still remains unclear, ADMA levels could be related to immune
activation in CA. In addition, these data might suggest the higher ADMA levels in patients could be due to the
perivascular inflammation and vasculitis in CA.
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Nitric oxide (NO) is reported to be an important me-
diator of vascular tone. Asymmetric dimethylarginine
(ADMA) has been shown to be the main endogenous
inhibitor of NO synthase and it regulates NO formation.
High ADMA levels have been shown to be related to
disorders causing vascular inflammation, such as hyper-
tension, hypercholesterolemia, atherosclerosis, chronic
heart failure, stroke, and sepsis. Therefore, ADMA is
considered to be associated with endothelial dysfunction.
Furthermore, ADMA is considered to be a predictive
marker of mortality in critically ill patients [1-4].
Anthrax is a rare, potentially fatal zoonotic disease
caused by the bacterium Bacillus anthracis, which can in-
fect both animals and humans [5]. Infection via inhalation* Correspondence: cenkaypak@yahoo.com
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article, unless otherwise stated.of Bacillus anthracis spores can result in a mortality rate
of up to 96% [5,6]. Cutaneous anthrax (CA), the most
common form of the disease, accounts for 95% of all an-
thrax cases [7]. It is acquired when spores enter through
a cut in the skin; it is characterized by the formation of
a black scar surrounded by prominent edema and vesi-
cles, and it is reported to cause vasculitis [6]. Bacteremia
and toxemia following cutaneous infection can lead a fa-
tality rate ranging from 20% to 25% among untreated
cases [6,7].
This study aimed to evaluate the serum ADMA levels
in patients with CA.Material and methods
Sera
In total, sera samples from 35 patients with accurate
diagnosis of CA were included in the study. Of these,
five sera samples were collected from patients admitted
into the clinics at Abant Izzet Baysal University (AIBU)entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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were collected from patients at Yuzuncu Yil University
Faculty of Medicine. Eighteen healthy subjects without a
history of chronic or recurrent disease served as the
controls.
The study protocol was approved by the local ethics
committee. All the subjects were informed about the
study, and written consent was obtained from each
subject.
Testing for ADMA levels
The symmetric dimethylarginine levels were tested using
an ADMA ELISA kit (Immunodiagnostik AG, Bensheim,
Germany) via the ELISA method in the Department of
Medical Biochemistry at the AIBU Faculty of Medicine.
Statistical analysis
The continuous variables were tested for normality using
the Shapiro-Wilk test. The normally distributed values
were presented as mean values (± standard deviation);
otherwise, they were presented as median values (the
interquartile range). A Chi-square test was used for in-
tergroup comparisons. An independent sample T test or
a Mann–Whitney U test was used for comparison be-
tween the two groups. Spearman’s rank correlation test
or Pearson correlation test was used for the correlation
and relationship between the indicated parameters. The
serum ADMA level’s capacity to predict the presence of
the disease in patients was analyzed using receiver oper-
ating characteristic (ROC) curve analysis. The sensitivity
and specificity were presented when a significant cut-off
value was observed. A p value of less than 0.05 was con-
sidered to be statistically significant.
Results
No significant differences were found between the
groups in terms of age and gender. The ADMA levels
were found to be significantly higher in patients with
CA than they were in the healthy controls (p < 0.001)
(Table 1). In the correlation analysis, the ADMA levels
were found to be positively associated with sedimenta-
tion rates (R = 0.413; p = 0.026), and they were found to
be inversely associated with international normalized
ratio (INR) levels (R = −0.46; p = 0.011). No associationTable 1 Differences between the groups according to
age, gender and ADMA levels
Variables Control group Patient group p
Age (Mean ± SD) 35.76 ± 18.43 37.32 ± 21.69 0.41
Gender (Male/Female) 9/9 13/22 0.37
ADMA level [Median (IQR)] 0.44 (0.13) 0.59 (0.26) <0.001
SD: Standard deviation; IQR: Interquartile range.was found between ADMA and the rest of the other la-
boratory variables (Table 2). In the ROC analysis per-
formed to predict the ADMA levels in patients, a cut-off
value of 0.475 had a sensitivity of 74.3%, specificity of
77.8%, positive predictive value of 86.7%, negative pre-
dictive value of 60.9%, and accuracy of 75.5 (AUC: 0.801;
p < 0.001; LB:0.675; UB: 0.927; CI 95%) (Figure 1).
Discussion
ADMA, a non-selective strong inhibitor of NO syn-
thase, is accepted to be a biomarker of endothelium
dysfunction [8]. ADMA was shown to be increased
in hypercholesterolemia, hyperhomocysteinemia, hyper-
tension, diabetes mellitus, insulin resistance, chronic
heart failure, hyperthyroidism, hemorrhagic shock, pre-
eclamptic pregnancy, multi-organ failure, and sepsis
[8-13]. Those results indicate that the synthesis and re-
lease of ADMA could be increasing during inflamma-
tion. Moreover, it was considered that NO and ADMA
play a role in the pathogenesis of many cutaneous
diseases [1,7,14-16]. Rowe et al. showed increased NO
synthase expression levels in patients with atopic der-
matitis, allergic dermatitis, and psoriasis [1]. Sahin et al.
found both ADMA and NO levels to be significantly
higher in patients with Behcet’s disease [15]. In addition,
increased NO was reported to be associated with other
inflammatory diseases, such as rheumatoid arthritis,
systemic lupus erythematosus, Sjögren’s syndrome, vas-
culitis, and osteoarthritis [15].
Although its incidence in developed countries has been
very low owing to improvements in animal husbandry and
handling of animal products, anthrax captured attention
after October 2001 because of bioterrorism attack through
the United States postal system and the subsequent identi-
fication of anthrax in 22 patients, including 11 with cuta-
neous disease [6,17,18]. CA is still endemic in the eastern
and southeastern regions of Turkey due to the presence of
uncontrolled livestock [14]. CA frequently occurs with dir-
ect contact with infected animals through a skin cut or an
abrasion. The infection was transmitted to all of our pa-
tients in the same way.
In the present study, the ADMA levels were found to
be significantly higher in the CA patients than in the
controls, which is consistent with other inflammatory
skin disorders. Although the exact mechanism under-
lying the increased ADMA levels in CA patients is not
clear, this increase could be due to perivascular inflam-
mation and vasculitis in CA, which was previously re-
ported [6]. Shieh et al. found vasculitis and various
degrees of inflammation were present in the lower epi-
dermis and dermis of CA case specimens. Warfel et al.
also showed endothelial dysfunction in anthrax [16]. Un-
fortunately we did not obtain skin biopsy samples of our
cases.
Table 2 The correlations between different variables in the patients group
Variables ADMA CRP Sedimentation WBC
r p r p r p r p
Age −0.096 0.59 −0.15 0.43 0.307 0.11 −0.222 0.22
ADMA
CRP 0.24 0.2
Sedimentation 0.413 0.026 0.28 0.14
WBC 0.076 0.68 0.289 0.12 0.008 0.97
ALT −0.049 0.79 0.156 0.4 0.086 0.66 0.025 0.89
AST 0.172 0.34 0.286 0.11 −0.18 0.35 0.268 0.14
Albumin 0.092 0.64 −0.016 0.94 0.097 0.65 0.08 0.69
Glucose 0.052 0.78 −0.215 0.25 0.068 0.72 0.057 0.76
Urea 0.144 0.46 0.37 0.06 0.582 0.002 0.319 0.1
Creatinine −0.003 0.99 0.035 0.85 0.296 0.2 0.241 0.18
PT −0.33 0.08 0.17 0.38 0.255 0.2 0.238 0.21
INR −0.46 0.011 0.291 0.13 −0.09 0.66 0.18 0.34
ADMA: Asymmetric dimethylarginine CRP: C-reactive protein WBC: White blood cell AST: Aspartat amino transferase ALT: Alanin amino transferase PT: Prothrombin
time INR: International normalized ratio.
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with HIV and it was stated that increased ADMA pro-
duction might be related to increased activity in the im-
mune system [19]. In addition, a decrease in ADMA
levels was shown in HIV patients undergoing antire-
troviral therapy [20]. The positive association betweenFigure 1 In the ROC analysis performed to predict ADMA levels
in anthrax patients, a cut-off value of 0.475 had a sensitivity of
74.3%, specificity of 77.8%, positive predictive value of 86.7%,
negative predictive value of 60.9%, and accuracy of 75.5
(AUC: 0.801; p < 0.001; LB:0.675; UB: 0.927; in confidence
interval of 95%).ADMA and sedimentation rate, which was shown in our
study, is consistent with the hypothesis of increased
ADMA levels and could be related to immune activation.
Although to our knowledge, this is the first study to
investigate serum ADMA enzyme activity in patients
with CA, it has limitations. First, our study design has
not allowed us to investigate if ADMA activity is
uniquely associated with CA. May be, a third group of
sick patients, with elevated inflammatory biomarkers,
but without increased ADMA levels, could have been
included to highlight the issue ideally. Second, as it was
mentioned previously we did not obtain skin biopsies to
evaluate the histopathologic changes including perivas-
cular inflammation. However, in the current study, we
observed that serum ADMA levels were significantly
higher in patients with CA than in the healthy controls.
In conclusion, our results suggest that ADMA con-
tributes to the inflammation which is seen in CA. Fur-
ther studies are needed in order to highlight the role
that ADMA plays in the mechanism and the pathoge-
nesis of CA.
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